Document Detail

The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
MedLine Citation:
PMID:  11277347     Owner:  NLM     Status:  MEDLINE    
Elderly patients with acute myelomonocytic leukaemia (AMMoL) frequently have a poor quality of life after induction of remission using high-intensity treatment; we seek a more appropriate regimen for such patients. An 86-year-old man was hospitalized with a diagnosis of AMMoL (FAB classification M4), of abnormal karyotype, and complications of diabetes mellitus and complete right bundle branch block. He was treated with CAG therapy (cytarabine 10 mg/m2 subcutaneously every 12 h for 14 consecutive days; aclarubicin hydrochloride 10 mg/m2 per day, bolus intravenously for 4 consecutive days; granulocyte colony-stimulating factor 100 microg/day, subcutaneous injection for 14 consecutive days) every 3 months. White blood cell counts were at their lowest (around 600 - 800/microl) 12 days after the end of therapy, but returned to about 2000 - 2300/microl 30 days after stopping therapy. No symptoms of drug-related toxicity, except slight nausea, were found. Complete remission with a good quality of life was induced and lasted over 2 years suggesting that CAG therapy might prove effective in elderly patients with AMMoL.
T Tsuda; Y Okamoto; R Sakaguchi; N Katayama; K Ota
Related Documents :
19697297 - Gender differences in the relationship between depression and cardiac autonomic functio...
563187 - Age, chronic obstructive pulmonary disease, and innovar induced ventilatory depression ...
21988667 - The use of the asthma control test in general practice and its correlation with asthma ...
10967367 - Correlates of symptomatic, minor and major depression in the elderly.
10899277 - Sexual activity and cardiac risk: is depression a contributing factor?
9626717 - The role of exposure with response prevention in the cognitive-behavioural therapy for ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Journal of international medical research     Volume:  29     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:    2001 Jan-Feb
Date Detail:
Created Date:  2001-03-29     Completed Date:  2001-07-19     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  41-7     Citation Subset:  IM    
Department of Blood Transfusion Medicine and Clinical Hematology, Wakayama Medical College, Wakayama City, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aclarubicin / therapeutic use*
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / therapeutic use*
Granulocyte Colony-Stimulating Factor / therapeutic use*
Leukemia, Myelomonocytic, Acute / drug therapy*,  pathology
Reg. No./Substance:
0/CAG protocol; 143011-72-7/Granulocyte Colony-Stimulating Factor; 147-94-4/Cytarabine; 57576-44-0/Aclarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiac beriberi among illegal mainland Chinese immigrants.
Next Document:  C-reactive protein values and erythrocyte sedimentation rates after total hip and total knee arthrop...